Boryung Pharm Cash Flow-to-Debt Ratio
Boryung Pharm cash flow-to-debt ratio. Boryung Pharm (003850) has a Cash Flow-to-Debt Ratio of 0.09x as of September 2025, meaning its operating cash flow of ₩48.95 Billion could theoretically repay 0% of its total liabilities (₩537.67 Billion) in one year. Check Boryung Pharm cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Boryung Pharm (2009–2024)
Cash flow-to-debt ratio of Boryung Pharm from 2009 to 2024. Historical debt coverage capacity for Boryung Pharm across 13 annual periods. Check 003850 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Boryung Pharm Cash Flow-to-Debt Ratio by Year (2009–2024)
Boryung Pharm cash flow-to-debt ratio by year from 2009 to 2024. Year-by-year debt coverage analysis for Boryung Pharm. For the full cash flow conversion analysis, see 003850 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩80.56 Billion | ₩379.58 Billion | ▲ +84.1% |
| 2023 | 0.12x | ₩42.22 Billion | ₩366.26 Billion | ▲ +55.8% |
| 2022 | 0.07x | ₩27.81 Billion | ₩375.97 Billion | ▼ -56.4% |
| 2021 | 0.17x | ₩60.17 Billion | ₩354.33 Billion | ▲ +16.8% |
| 2020 | 0.15x | ₩44.74 Billion | ₩307.71 Billion | ▼ -30.5% |
| 2019 | 0.21x | ₩47.00 Billion | ₩224.68 Billion | ▲ +4.2% |
| 2018 | 0.20x | ₩38.91 Billion | ₩193.91 Billion | ▲ +224.6% |
| 2017 | -0.16x | ₩-24.61 Billion | ₩152.86 Billion | ▼ -448.3% |
| 2016 | 0.05x | ₩9.36 Billion | ₩202.55 Billion | ▼ -68.0% |
| 2012 | 0.14x | ₩18.38 Billion | ₩127.21 Billion | ▲ +95.7% |
| 2011 | 0.07x | ₩9.19 Billion | ₩124.42 Billion | ▼ -66.5% |
| 2010 | 0.22x | ₩24.12 Billion | ₩109.45 Billion | ▲ +223.6% |
| 2009 | 0.07x | ₩3.59 Billion | ₩52.77 Billion | — |